IDH2 and acute myeloid leukemia: It is important to note that the clinical drug Enasidenib (AG-221) used in clinical treatment of AML is a specific inhibitor of mutant IDH2 [17], and thus is unlikely to inhibit wild-type IDH2 effectively.